The University of Alabama at Birmingham is sponsoring a clinical trial to evaluate a 6-week virtual yogic breathing exercise program for individuals with amyotrophic lateral sclerosis (ALS) and myasthenia gravis. This study addresses a niche market focused on non-pharmacological interventions for ALS, which currently lacks extensive therapeutic options. The trial's outcomes may provide valuable insights into complementary therapies that could enhance quality of life for ALS patients, potentially leading to partnerships with wellness and rehabilitation organizations. Given the increasing interest in holistic and integrative health approaches, successful results could position the sponsor favorably within the growing market for ALS management solutions. However, the absence of a pharmaceutical intervention may limit traditional investor interest.